The Certificate in Psychedelic-Assisted Therapies by Mind Medicine Australia (MMA CPAT) has been developed primarily to meet the anticipated demand for trained therapists to provide regulatory-approved and research-backed psychedelic-assisted therapies for the treatment of mental ill-health in Australia. It is also expected that trained clinicians will be needed to work in research trials as they expand in Australia.
The training certificate follows world best practice following review of current practices including protocols developed by MAPS and the REBUS model developed at Imperial College London.
The development of the MMA program has relied on significant collaboration with colleagues with considerable psychotherapeutic skill and knowledge. The teaching program incorporates live face-to-face lectures and webcasts, self-study and direct teaching of skills and experiential workshops led by this team. For more details of members of the teaching team please see below.
While incorporating the best of components from courses overseas, the Certificate in Psychedelic-Assisted Therapies is also offered in the spirit of respect and acknowledgement of the local context within Australia. The 2021 program is the very first course of its kind in the Southern Hemisphere.
Mind Medicine Australia has listened to feedback from people keen to participate and has developed the course length and requirements to be accessible to people who are travelling from all over Australia and beyond. We also understand the need to make the course as widely available as possible to working therapists, who have time and financial pressures shaping their capacity to meet the demands of the course.
The original courses require practical elements – participation in research programs, etc., which are not yet as widely available in Australia as overseas. Mind Medicine Australia has nonetheless been committed to maintaining the highest quality possible, and so the course presents academic, didactic and skills development components in a similar hybrid model of online, live and self-study components as the CIIS course. We expect that as the course grows and graduates establish themselves and more opportunities will arise, including the possibility of incorporating learning by placements, shadowing, etc.
We also offer a Psychological Support Service currently, part of which enables clinicians working in the field to access supervision and on-going professional development – more details below.
We are also aware that there is a very long history of traditional use of these substances (as well as others not as well known) and practices for various healing and spiritual growth purposes in every continent in the world. Teaching about this history is part of the course. Incorporating input from traditional practitioners from various sources is an ambition we hold with high value for the future as reality permits.
For now, our focus is to start with training therapists primarily focussed on meeting the needs of the mental health crisis, working within research programs and a medically supported environment, and providing integrative and other therapeutic work with the users of these substances.
The course will take place over a period of 4 months, with:
The Certificate in Psychedelic-Assisted Therapies course aims to build on skills already acquired and used by professionals working in various therapeutic contexts. Applicants must have as a minimum a Bachelor level degree in a field relevant to mental health, plus at least 3 years of documented supervised practice in a mental health field.
On this basis, people with the following qualifications may apply:
Acceptance onto the course will rest on three main factors:
The focus of Mind Medicine Australia is on the clinical application of medicinal psilocybin and medicinal MDMA for certain classes of mental illness in a regulatory approved manner. At the current time, these treatments are only legally available in Australia in particular circumstances (which can differ from State to State), and then only after specific regulatory approvals have first been obtained. Given this legal position we cannot accept any person into the course if we believe, on reasonable grounds, that that person is using or intends to use, these treatments in breach of the law. We also cannot condone in any way the illegal use of these substances.
Application fee: $150 (non-refundable)
Course fee: $7500 (or $7000 upfront payment in full)
Course 1: 30 January to 22 May 2021
Pre-reading: Will be emailed on 13 December 2020
|First meeting:||30 January 2021|
|Final meeting:||22 May 2021|
|Week-long Intensive:||25 to 30 April 2021|
|Final submission of coursework:||31 May 2021|
|Supervised practice:||To be arranged*|
Course 2: 26 June to 9 October 2021
Pre-reading: Will be emailed on 21 May 2021
|First meeting:||26 June 2021|
|Final meeting:||9 October 2021|
|Week-long Intensive:||12 to 17 September 2021|
|Final submission of coursework:||16 October 2021|
|Supervised practice:||To be arranged*|
Course 3: 22 January to 30 May 2022
Pre-reading: Will be emailed on 12 December 2021
|First meeting:||22 January 2022|
|Final meeting:||21 May 2022|
|Week-long Intensive:||1 to 5 May 2022|
|Final submission of coursework:||30 May 2022|
|Supervised practice:||To be arranged*|
Course 4: 23 July to 29 October 2022
Pre-reading: Will be emailed on 20 May 2022
|First meeting:||23 July 2022|
|Final meeting:||22 October 2022|
|Week-long Intensive:||2 to 7 Oct 2022|
|Final submission of coursework:||29 Oct 2022|
|Supervised practice:||To be arranged*|
* Subject to regulatory requirements
Are open for intakes 2-4 (Applicants will be considered in order of receipt. We expect the program to be over-subscribed so please register early to avoid disappointment.)
Screening and interview/finalise applicants:
July/August 2021 for intake 3
Step 1: Complete the Application Form.
Step 2: Send your $150 application processing fee including your initial course fee ($7150 – discounted upfront full fee or $2650 part fee): Mind Medicine Australia via Paypal or Credit Card Payment (part of the application form).
Step 3: Applications will be screened, and if successful invited to an interview in July.
Step 4: Final decision, and invitation to join the course.
Gabby Agin-Liebes, PhD is a clinical psychologist with 10 years of experience working as a therapist and investigator on academic trials with psilocybin-assisted therapy at New York University, Yale and UC San Francisco (UCSF). Her research has applied quantitative and qualitative methodologies within psilocybin-assisted and mindful self-compassion-based interventions to treat substance use and trauma-based disorders. She is currently a National Institutes of Health-funded research fellow at UCSF studying novel interventions for treating opioid addiction and chronic pain that target dysregulated emotion regulation and attentional bias processes. She is the lead author on a paper published earlier this year, and featured in several news outlets, which found that psilocybin-therapy led to sustained clinical remission from depression and anxiety in individuals with cancer up to 4.5 years later.
Wade Davis is a writer and photographer whose work has taken him from the Amazon to Tibet, Africa to Australia, Polynesia to the Arctic. Explorer-in-Residence at the National Geographic Society from 2000 to 2013, he is currently Professor of Anthropology and the BC Leadership Chair in Cultures and Ecosystems at Risk at the University of British Columbia.
Wade has authored 22 books, including One River, The Wayfinders and Into the Silence, he holds degrees in anthropology and biology and received his Ph.D. in ethnobotany, all from Harvard University. In 2016, he was made a Member of the Order of Canada. In 2018 he became an Honorary Citizen of Colombia.
Nigel Denning MA, MPsych is a Counselling Psychologist, AHPRA registered supervisor and Managing Director of Integrative Psychology a Psychology/Psychiatry practice in East Melbourne. He is a former Family Violence Co-ordinator for Relationships Australia and is currently the Deputy President of the In Good Faith Foundation, an organisation that supports Institutional Abuse and cult survivors. Nigel is also a registered Neuro-psychotherapy supervisor with IAAN.
Nigel has been involved in Transpersonal Psychology and consciousness studies for over thirty years. He has studied extensively under Stanislav Grof MD and worked closely with Tav Sparks and Grof Transpersonal Training to develop training approaches to Holotropic breathwork and therapy influenced by this modality. Nigel also conducted one of the few peer reviewed research studies on HB.
Nigel teaches and has presented at numerous national and international conferences on state change technology, including medicine work. Nigel also has an established practice in Tibet Bon Dzogchen meditation under the guidance of Dr Daniel Brown of Harvard Medical School.
Rick Doblin, Ph.D., is the founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS). He received his doctorate in Public Policy from Harvard’s Kennedy School of Government, where he wrote his dissertation on the regulation of the medical uses of psychedelics and marijuana and his Master’s thesis on a survey of oncologists about smoked marijuana vs. the oral THC pill in nausea control for cancer patients. His undergraduate thesis at New College of Florida was a 25-year follow-up to the classic Good Friday Experiment, which evaluated the potential of psychedelic drugs to catalyze religious experiences. He also conducted a thirty-four year follow-up study to Timothy Leary’s Concord Prison Experiment. Rick studied with Dr Stanislav Grof and was among the first to be certified as a Holotropic Breathwork practitioner. His professional goal is to help develop legal contexts for the beneficial uses of psychedelics and marijuana, primarily as prescription medicines but also for personal growth for otherwise healthy people, and eventually to become a legally licensed psychedelic therapist. He founded MAPS in 1986, and currently resides in Boston with his wife and empty rooms from three children who are all in college or recently graduated.
Dr Tra-ill Dowie is the Head of the Faculty of Psychotherapy at Ikon Institute Australia. Dr Dowie is the Chair of the Australian Counselling Association (ACA) Panel for Trauma Standards & Practice. Dr Dowie is a practising psychotherapist, supervisor and public speaker.
Dr Dowie’s academic life and public lectures cover a broad range of interdisciplinary topics that relate to the human condition: psychiatry, psychotherapy, trauma, continental philosophy, philosophy of mind, anthropology, health and wellbeing, and human optimisation.
He holds dual PhDs, receiving a PhD in Psychiatry from Monash University and a PhD in Philosophy from the University of Melbourne.
James Fadiman B.A. (Harvard) M.A., Ph.D. (Stanford) began his personal psychedelic research a few weeks before starting his graduate work at Stanford where he did his dissertation on the effectiveness of LSD-assisted therapy. During the research lull of 40 years, he has held a variety of teaching (San Francisco State, Brandeis, and Stanford) consulting, training, counseling and editorial positions. He has taught in psychology departments, design engineering, and for three decades, at the Institute of Transpersonal Psychology (now Sofia University) that he co-founded.
He has published textbooks, professional books, a self-help book, a novel, and a series of videos, Drugs: the children are choosing for National Public Television. His books have been published in 8 languages. He has been the subject of a one-hour documentary released by Page3 Films, featured in a National Geographic documentary and had three solo shows of his nature photography.
He had his own consulting firm and sat on two non-profit boards as well as having been the president of several small natural resource companies. He has been involved in researching psychedelic for spiritual, therapeutic and creative uses and is known for his pioneering work on microdosing . He has published The Psychedelic Explorer’s Guide: Safe, Therapeutic, and Sacred Journeys, and most recently, Your Symphony of Selves: Discover and Understand More of Who You Are
Dr Ingmar Gorman is the co-founder of Fluence, a psychedelic education company training mental health providers in psychedelic treatments. He is a psychologist specializing in helping people who use psychedelics and other psychoactive compounds. He received his clinical training at the New School for Social Research, Mount Sinai Beth Israel Hospital, Columbia University, and Bellevue Hospital. He completed his NIH postdoctoral fellowship at New York University in 2017. Dr Gorman was formerly the Director of the Psychedelic Education and Continuing Care Program, formerly site co-principal investigator and current active therapist on a Phase 3 clinical trial of MDMA-assisted Psychotherapy for Post-Traumatic Stress Disorder and active therapist on a Phase 2 clinical trial of Psilocybin-assisted Psychotherapy for Treatment Resistant Depression.
Albert Garcia-Romeu, Ph.D. is a member of the Psychiatry and Behavioral Sciences faculty at the Johns Hopkins University School of Medicine and a Guest Researcher at the National Institute on Drug Abuse Intramural Research Program. His research examines the effects of psychedelics in humans, with a focus on psilocybin as an aid in the treatment of addiction. He received his doctorate in Psychology in 2012 from the Institute of Transpersonal Psychology in Palo Alto, CA, where he studied self-transcendence and meditation, and their relationship to mental health. His current research interests include clinical applications of psychedelics, mindfulness, and altered states of consciousness and their underlying psychological mechanisms. He additionally studies real-world drug use patterns and impacts on public health, and the role of spirituality in mental health and addiction. He is a founding member of the Johns Hopkins Center for Psychedelic and Consciousness Research and the International Society for Research on Psychedelics.
As an investment banker Peter Hunt AM advised local and multi-national companies and governments in Australia for nearly 35 years. He co-founded and was Executive Chairman of one of Australia’s leading investment banking advisory firms, Caliburn Partnership (now called Greenhill Australia) and continued as Chairman of the Firm after its sale to Greenhill Inc in 2009. Peter was a member of the Advisory Panel of ASIC and chaired the Vincent Fairfax Family Office.
Peter is an active philanthropist involved in funding, developing and scaling social sector organisations which seek to create a better and fairer world. He is Chairman of Mind Medicine Australia which he established with his wife, Tania de Jong, in 2018. He founded Women’s Community Shelter in 2011 and remains on the Board. He is Chairman of So They Can, Grameen Australia and Grameen Australia Philippines. Peter is a Director of Project Rozana and an Advisory Board member of the Monash Sustainable Development Institute. Peter also acts as a pro bono adviser to Creativity Australia.
Peter was made a member of the General Division of the Order of Australia in the Queen’s Birthday Honours List in 2010 for services to the philanthropic sector.
LL.B (Hons), GradDipMus
Tania de Jong AM is a trail-blazing Australian soprano, award-winning social entrepreneur, creative innovation catalyst, spiritual journey woman, storyteller and global speaker. She has a Bachelor of Law (Honours) from University of Melbourne and is a graduate in opera and music theatre from the Victorian College of the Arts.
Tania is one of Australia’s most successful female entrepreneurs and innovators developing 5 businesses and 3 charities including Creative Universe, Creativity Australia and With One Voice, Creative Innovation Global, Mind Medicine Australia, Dimension5, MTA Entertainment & Events, Pot-Pourri and The Song Room.
She works across the public, private, creative and community sectors and is passionate about mental health, innovation, diversity and inclusion. Tania speaks and sings around the world as a soloist and with her group Pot-Pourri releasing twelve albums. She is Founder and Executive Producer of future-shaping events series, Creative Innovation Global.
She was appointed a Member of the Order of Australia in June 2008 and was recently named one of the 100 Women of Influence and the 100 Australian Most Influential Entrepreneurs.
Tania’s TED Talk ‘How Singing Together Changes The Brain’ has sparked international interest. Tania’s mission is to change the world, one voice at a time!
Mendel Kaelen is the founder and CEO of Wavepaths. Prior to this, he worked as a PhD and postdoctoral neuroscientist at Imperial College London for 7 years, where his research was the first to demonstrate music’s central role in psychedelic therapies. He developed methods and protocols for the use of music to enhance therapy outcomes and out of this, the vision for Wavepaths. He is a thought leader on the therapeutic use of music and publishes and speaks frequently on this topic. He has been featured in Nature News, San Francisco Chronicles, Vice Motherboard, Rolling Stone and TEDx. Mendel’s work is driven heavily by his personal work with psychedelic medicines and psychotherapies that started 15 years ago. He lives and works in London (UK), and in his spare time likes to get into nature, and to get out of his mind with his Shakuhachi and modular synthesiser.
BA, MD, Doctor of Laws (honoris causa)
Gabor Maté (pronunciation: GAH-bor MAH-tay) is a retired physician who, after 20 years of family practice and palliative care experience, worked for over a decade in Vancouver’s Downtown East Side with patients challenged by drug addiction and mental illness. The bestselling author of four books published in twenty-five languages, Gabor is an internationally renowned speaker highly sought after for his expertise on addiction, trauma, childhood development, and the relationship of stress and illness.
His book on addiction received the Hubert Evans Prize for literary non-fiction. For his groundbreaking medical work and writing he has been awarded the Order of Canada, his country’s highest civilian distinction, and the Civic Merit Award from his hometown, Vancouver. His books include In the Realm of Hungry Ghosts: Close Encounters With Addiction; When the Body Says No; The Cost of Hidden Stress; Scattered Minds: The Origins and Healing of Attention Deficit Disorder; and (with Gordon Neufeld) Hold on to Your Kids: Why Parents Need to Matter More Than Peers. To learn more, join his enews list at www.drgabormate.com.
Friederike Meckel trained as a medical doctor and a medical psychotherapist in Germany. From 1989-1991 she trained as a Holotropic Breathwork© facilitator with Prof. Stanislav Grof in the US. Friederike began to realize the additional therapeutical benefits of psychoactive substances through her own experiences. She happened to have the extraordinary good fortune to join a psychotherapeutic training group which instructed therapists in the use of psycholytic psychotherapy with MDMA and LSD in the early nineties in Switzerland. She also trained as a couple’s therapist, a family therapist and a family-constellation-worker. In 1994, she started working in her own private psychotherapeutic practice providing non-drug psychotherapy, Holotropic Breathwork©-groups and systemic-family-constellation work. Over a couple of years, she started developing her specific way of psychotherapy with the use of psychedelics, working underground, in groups, with specifically chosen clients. She speaks about her work in conferences and interviews.
David E. Nichols, PhD is an Adjunct Professor of Chemical Biology and Medicinal Chemistry at the University of North Carolina, Chapel Hill. Previously he held the Robert C. and Charlotte P. Anderson Distinguished Chair in Pharmacology and was a Distinguished Professor of Medicinal Chemistry and Molecular Pharmacology at the Purdue University College of Pharmacy. He received his B.S. degree in chemistry from the University of Cincinnati in 1969, and the PhD in Medicinal Chemistry from the University of Iowa in 1973, following which he did postdoctoral work in pharmacology at the University of Iowa, College of Medicine. In 2004 he was named the Irwin H. Page Lecturer by the International Society for Serotonin Research and in 2006 he received the first Provost’s Outstanding Graduate Mentor award from Purdue University. He has published more than 300 scientific articles, most of which deal with the relationship between molecular structure and biological action.
BA, MB BChir, MRCP, MA, DM, MRC Psych, FRCPsych, FMedSci, FRCP, FSB
Renowned researcher, policy advisor and author, Professor David Nutt, is currently Head of Neuropsychopharmacology at Imperial College London.
Under the leadership of Professor Nutt, the Psychedelic Research Group at Imperial College is one of the world’s foremost psychedelic research laboratories, publishing landmark research on psychedelic therapies and neuroimaging studies of the psychedelic state.
Professor Nutt has also held many leadership positions in both UK and European academic, scientific and clinical organisations, including presidencies of: the European Brain Council, the British Neuroscience Association, the British Association of Psychopharmacology, the European College of Neuropsychopharmacology.
He was previously Chair of the UK Advisory Council on the Misuse of Drugs.
M.D., FRACGP, FACRRM, FACHAM (RACP)
Dr Nikola Ognyenovits is a Hungarian born Australian Addiction Medicine Specialist Physician living in Brisbane, Australia. He works in public alcohol and drug services and in private practice. After graduating as M.D. in 1987, he trained and worked in psychiatry, rural general practice, emergency medicine and aero-medical retrievals.
He was introduced to non-ordinary states of consciousness through Holotropic Breathwork and had the privilege of learning from Stanislav Grof and Tav Sparks. Dr Nikola has co-facilitated numerous breathwork sessions, trained with the Foundation of Shamanic Studies and participated in shamanic healing traditions globally.
After training in Ketamine Assisted Psychotherapy with The Ketamine Training Center, he has incorporated ketamine treatment into his private practice. He sees great potential in the application of ibogaine for addictions and has supported clients pre and post treatment. Dr Nikola is an advocate of the ethical and controlled use of psychedelic assisted psychotherapies in the treatment of addictions and associated mental health conditions.
William A. Richards (Bill), a psychologist in the Center for Psychedelic
and Consciousness Research at the Johns Hopkins School of Medicine, has been
implementing research studies with psilocybin since 1999. His graduate degrees
include M.Div. (Yale) , S.T.M. (Andover-Newton) and Ph.D. (Catholic
University). He also studied with Abraham Maslow at Brandeis University and
with Hanscarl Leuner at Georg-August University in Göttingen, Germany, where
his involvement with psilocybin research originated in 1963. From 1967 to 1977,
he implemented projects of psychotherapy research with LSD, DPT, MDA and
psilocybin at the Maryland Psychiatric Research Center, including protocols
designed to investigate the promise of psychedelics in the treatment of alcoholism,
depression, narcotic addiction and the psychological distress associated with
terminal cancer, and also their use in the training of religious and mental-health
professionals. His book, Sacred Knowledge: Psychedelics and Religious
Experiences has been released by Columbia University Press.
PH.D Psychology, B. A Social Work (MHSW)
Dr Alana Roy is a psychologist, social worker and therapist and has spent the last 13 years working in mental health, suicide prevention, trauma, sexual abuse and family violence and the disability sector. Alana has worked with borderline personality and dissociative identity disorder in various roles in the community such as; Rape Crisis Centers with victims of ritual abuse, childhood and adult sexual assault, supporting women in the sex industry, survivors of human trafficking and now as a psychedelic integration specialist. Alana focuses on harm minimisation, community and connection. She is dedicated to psychedelic assisted psychotherapy and plant medicines. She has engaged with, and provides integration therapeutic support services for communities across Australia. Alana works at several universities as a Research Fellow and supervisor of students on placement. Alana passionately advocates for public policy, community education and legislative changes so that these treatments are regulated and supported by a strong, connected and skilled sector. Alana utilizes a range of therapies such as emotion focused therapy, Eye Movement Desensitization and Reprocessing (EMDR), cognitive-behavioural therapy, acceptance and commitment therapy and mindfulness and meditation approaches. In Alana’s spare time she is kept busy by her young sons, her love of travelling the world, and connecting with the diverse and creative medicine community.
Dr Arne Rubinstein is an internationally recognised expert on Rites of Passage. His trainings and programs have been attended by over 200,000 people in more than 20 countries around the world and are now a part of over 50 schools around Australia.
Dr Arne is a medical doctor and specialised first in Family Medicine and then spent 15 years in Emergency Medicine until he moved full time creating Rites of Passage globally.
He is the author of the best-seller The Making of Men and has won multiple awards for his work including being nominated in 2008 for Australian of the Year for his groundbreaking work.
He has worked in Europe, The USA, Bhutan, Israel, Indonesia and supported the re-introduction of Rites of Passage for the Butchulla Aboriginal mob in Queensland. He is passionate about Rites of Passage becoming mainstream once again.
Dr Arne is the proud father of two wonderful young men and a mentor to many others.
MBBS, B.SC, MRC PSYCH
Ben Sessa is a consultant child and adolescent psychiatrist who has worked with young people and adults in the field of addictions and trauma-related psychiatry for over 20 years. For the last 15 years Ben has been at the forefront of psychedelic research in the UK through his affiliations with Bristol University and Imperial College London, under the auspices of Professor David Nutt. He has taken part as a study doctor and as a healthy subject both receiving and / or administering MDMA, psilocybin, LSD, DMT and ketamine in multiple UK research studies. He runs one of the first UK-based medical cannabis prescribing clinics. Ben is the Chief Medical Officer at AWAKN Life Sciences, a new start-up company opening Europe’s first psychedelic medical clinic, which will be providing psychedelic therapies, therapist training courses and conducting independent research. Ben is the co-founder and former president of Europe’s largest psychedelic conference, Breaking Convention.
As an advocate for innovative solutions for mental health, Melissa is Education and Communications Officer at Mind Medicine Australia, Secretary of Psychedelic Research in Science and Medicine, co-founder of the Australian Psychedelic Society and is a member of the UK-Australian Young Leaders Forum.
After graduating in Neuroscience from the University of Melbourne, Melissa travelled to leading international centres of psychedelic research, transformative technology and Buddhist meditation to forecast next-generation mental health treatments. Melissa traverses the divide between research and therapeutic practice through her lived experience in healing from PTSD with psychedelic-assisted therapy internationally.
With a background in digital art, programming and performance art, Melissa brings a creative and future-focused outlook to her pursuits. Melissa is currently a post-graduate student at The University of Melbourne on the path towards clinical psychology and is creating therapeutic virtual reality programs to support psychedelic-assisted therapy and enhanced wellbeing.
Jeremy Weate has a PhD in philosophy from the University of Warwick. He has over 17 years strategic advisory experience, focused on minister-level guidance on the mining sector across over 50 projects in over 30 countries in Europe, Africa, Central Asia and the South Pacific. Jeremy also has a decade-long interest in the medicalization of ibogaine. In 2018, he helped set up Tabula Rasa Retreat in Portugal, now of the leading ibogaine treatment facilities globally. He has organised ibogaine conferences in Vienna, Porto and London. He is CEO of the Vancouver-based Universal Ibogaine, which will IPO on the Toronto Stock Exchange later this year. Universal Ibogaine will take ibogaine through clinical trials in Canada, with a view to multi-country phase 3 trials in Canada, Australia, New Zealand and Israel. The company will launch holistically minded psychedelic-assisted therapy clinics in North America and subsequently globally this decade under the ClearSky Recovery brand.
MBBS, DPM, FRANZCP
Raised and educated in Melbourne, Australia, Dr John Webber, MBBS, DPM, FRANZCP completed his medical degree at Melbourne University and his intern years at the Royal Melbourne Hospital. Initially drawn to a surgical path, he was eventually drawn by his heart and life circumstances to a career in psychiatry. His first years of psychiatric training were at the Royal Melbourne Hospital psychiatry department, and his training later included a year at the Melbourne Neuropsychiatry Centre. Dr Webber completed his specialist qualification through the Royal Australia and New Zealand College of Psychiatrists and has since worked in a successful private practice for over 30 years. His areas of interest include bipolar disorder, depressive disorders, hypnosis, and anxiety disorders, as well as mentoring young psychiatrists.
MORE TEACHERS TO BE ANNOUNCED... please watch this space
Mind Medicine Australia has developed a safe and professional psychological service for those who want support regarding psychedelics, plant medicines, and their emotional health and wellbeing.
By submitting an enrolment application for the Certificate in Psychedelic-Assisted Therapies (CPAT), you acknowledge that you have read and accepted these Terms and Conditions.
*Subject to regulatory requirements
Mind Medicine Australia is seeking to establish safe and effective psychedelic-assisted therapies for the treatment of mental illness in Australia. MMA is focused specifically on the clinical application of medicinal psilocybin and medicinal MDMA for the treatment of certain mental illnesses.
We do not advocate for recreational use of psychedelics, MDMA, or any other prohibited substances*, nor do we advocate for any changes to the law with respect to recreational use. Our focus is wholly clinical.
Mind Medicine Australia requires allied health professionals, psychotherapists and general participants wishing to participate in the Certificate in Psychedelic-Assisted Therapies to agree to the following Code of Conduct during the professional development program.
Participants will not:
Failure to follow these guidelines could result in losing a place in the CPAT program.
Thank you for working with us to ensure that we deliver a high quality, safe and reputable CPAT program.
* Psychedelics or psychedelic substances are described as ‘psychoactive substances’ by the Victoria State Government.